ClinicalTrials.gg
CompletedNCT04626596Updated Feb 18, 2026

A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)

A Phase 3 interventional study of Radiopaque Etonogestrel (ENG) Implant in Contraception, sponsored by Organon and Co. Completed at 67 sites in 2 countries. Open to female participants aged Up to 35 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Organon and Co · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
498
Allocation
Not applicable
Ages
Up to 35 Years
Sex
Female
01

Study summary

The primary purpose of this study is to assess the efficacy and safety of the etonogestrel (ENG) contraceptive implant during participants' fourth and fifth years of use when used as the only method of contraception. The ENG implant is currently approved for a 3-year duration, and this study aims to confirm available evidence suggesting that the ENG implant remains highly effective when used up to 5 years.

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Not diagnosed with perimenopause or menopause.
  • Heterosexually active with a partner who is not known to be subfertile, sterilized, or infertile, and is seeking for pregnancy.
  • Palpable intact ENG implant in the upper inner-arm for 36 months from the date of insertion at the time of enrollment, and has documentation of the insertion date (for example, Nexplanon user card or medical record completed on the date of insertion).
  • Does not desire a pregnancy within the 24 months after enrollment, is willing to continue use of the implant for an additional 24 months, and is not intending to use any other form of contraception (eg, condoms) from enrollment until after implant removal at 24 months post enrollment.
  • Good physical and mental health in the medical judgment of the investigator.
  • History of regular menstrual cycles of 21 to 35 days before the insertion of the ENG implant or before hormonal contraceptive use (which may have preceded the current implant use).
  • Able and willing to adhere to all required study procedures, including study visits and eDiary entries, and not planning to relocate during the study.

Exclusion criteria

Exclusion Criteria:

  • Conceived a pregnancy during use of the current implant or a past implant.
  • Known or suspected pregnancy at the time of screening or enrollment visit.
  • History of subfertility or infertility.
  • Breastfeeding.
  • Untreated gonorrhea, chlamydia, or trichomonas or symptomatic vaginitis/cervicitis.
  • Significantly abnormal cervical cytology (Pap) or pathology results either at screening or documented in the 36-month period prior to enrollment.
  • Current use of an intrauterine device/intrauterine system (IUD/IUS).
  • Presence of more than one ENG implant.
  • Use of daily/monthly hormonal contraceptives, sex , or GnRH agonist/antagonist within 3 months prior to enrollment.
  • Use of injectable hormonal contraceptive with 3-month duration within 9 months prior to enrollment.
  • Use of injectable GnRH agonist with 3-month duration within 10 months prior to enrollment .
  • Use of medications that induce liver enzymes within 2 months prior to enrollment.
  • Untreated or unresolved vaginal bleeding or spotting attributable to underlying pathology in the 12 months before screening.
  • Frequent, prolonged, or excessive vaginal bleeding/spotting in the 12 months prior to screening which has not been evaluated to detect underlying pathology.
  • History of venous thromboembolism or arterial thromboembolism, , angina pectoris, or claudication.
  • Any condition associated with an increased risk of venous thromboembolism.
  • Uncontrolled or severe hypertension at screening visit.
  • liver disease, including active viral hepatitis or cirrhosis.
  • History of within 5 years before screening, except treated skin cancer.
  • History of sex steroid-influenced malignancies (eg, genital organs, breasts).
  • History or presence of liver tumors (benign or malignant).
  • Known allergy/sensitivity or to the ENG implant or lidocaine with epinephrine.
  • History of drug or alcohol abuse or dependence within 24 months prior to enrollment. Routine use of alcohol or marijuana that is not considered abuse or dependence is not exclusionary.
  • Use of an drug within 2 months prior to enrollment. Long-term follow up of an investigational compound for COVID-19 is allowed 2 months after the last administered dose.
  • Staff or immediate family members of the investigational site or Sponsor directly involved with this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
498 participants (actual)

Study arms

  • Experimental
    ENG implant

    Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.

    Combination Product: Radiopaque Etonogestrel (ENG) Implant

Interventions

  • Combination productEtonogestrelStudies of EtonogestrelEtonogestrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    68 mg subdermal implant

    Also known as: Org 32222, Nexplanon, Implanon-NXT, SCH900415, MK-8415

06

What researchers measure

Primary outcomes

  1. Pregnancy Rate (Pearl Index) for At Risk Cycles During Extended-Duration Use

    The Pearl Index is expressed as the number of on-treatment pregnancies per 100 woman-years of exposure. An on-treatment pregnancy is defined as a confirmed pregnancy with an estimated date of conception 36 months to 60 months since the date of implant insertion. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "at risk" cycles for conception will be included in this Pearl Index calculation. An at risk cycle is defined as a cycle during which participants with ENG implant had affirmed heterosexual intercourse without the use of additional contraception.

    Time frame: Up to 24 months

  2. Pregnancy Rate (Pearl Index) for Alternative At Risk Cycles During Extended-Duration Use

    The Pearl Index is expressed as the number of on-treatment pregnancies per 100 woman-years of exposure. An on-treatment pregnancy is defined as a confirmed pregnancy conceived with an estimated date of conception 36 months to 60 months since the date of implant insertion. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "alternative at risk" cycles will be included in this Pearl Index calculation. An alternative at risk cycle is defined as a cycle in which participants with ENG implant did not use additional contraception, but without the requirement for affirmed heterosexual intercourse.

    Time frame: Up to 24 months

  3. Number of Participants Who Experience One or More Adverse Events During Extended-Duration Use

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 27 months

  4. Number of Participants Who Discontinue Treatment (Implant Removed) Due to an Adverse Event During Extended-Duration Use

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Pregnancy Rate (Pearl Index) for At Risk Cycles During Year 4 of Implant Use

    Pearl Index will be calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "at risk" cycles for conception will be included in this Pearl Index calculation. An at risk cycle is defined as a cycle during which participants with ENG implant had affirmed heterosexual intercourse without the use of additional contraception.

    Time frame: Up to 12 months

  2. Pregnancy Rate (Pearl Index) for At Risk Cycles During Year 5 of Implant Use

    Pearl Index will be calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "at risk" cycles for conception will be included in this Pearl Index calculation. An at risk cycle is defined as a cycle during which participants with ENG implant had affirmed heterosexual intercourse without the use of additional contraception.

    Time frame: Up to 12 months

  3. Cumulative Pregnancy Rate During 5 Years of Implant Use

    Cumulative on-treatment pregnancy rate will be calculated based on life table analysis over 5 years of implant use.

    Time frame: Up to 60 months (From 3 years prior to study entry to 2 years after study entry)

  4. Cumulative Pregnancy Rate During 4 Years of Implant Use

    Cumulative on-treatment pregnancy rate will be calculated based on life table analysis over 4 years of implant use.

    Time frame: Up to 48 months (From 3 years prior to study entry to 1 year after study entry)

  5. Pregnancy Rate (Pearl Index) for At Risk Cycles During 5 Years of Implant Use

    Pearl Index will be calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "at risk" cycles for conception will be included in this Pearl Index calculation. An at risk cycle is defined as a cycle during which participants with ENG implant had affirmed heterosexual intercourse without the use of additional contraception. The number of at-risk cycles of use for each of the 3 years prior to study entry will be estimated.

    Time frame: Up to 60 months (From 3 years prior to study entry to 2 years after study entry)

  6. Pregnancy Rate (Pearl Index) for Alternative At Risk Cycles During 5 Years of Implant Use

    Pearl Index will be calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "alternative at risk" cycles will be included in this Pearl Index calculation. An alternative at risk cycle is defined as a cycle in which participants with ENG implant did not use additional contraception, but without the requirement for affirmed heterosexual intercourse. The number of alternative at risk cycles of use for each of the 3 years prior to study entry will be estimated.

    Time frame: Up to 60 months (From 3 years prior to study entry to 2 years after study entry)

  7. Number of Bleeding Days During Extended-Duration Use as Assessed in 90-day Reference Periods

    Participants will record daily vaginal bleeding in an electronic diary. A bleeding day is defined as any day (24 hours) with bloody vaginal discharge requiring more than one sanitary product (i.e., pad, panty liner, tampon, or menstrual cup) or, if only a menstrual cup is used, more than 5 mL of blood accumulates. Number of bleeding days will be assessed per 90-day reference period (RP).

    Time frame: Up to 24 months

  8. Number of Spotting Days During Extended-Duration Use as Assessed in 90-day Reference Periods

    Participants will record daily vaginal spotting in an electronic diary. A spotting day is defined as any day (24 hours) with bloody vaginal discharge requiring at most one sanitary product (i.e. pad, panty liner, tampon, or menstrual cup containing 5 ml \[inclusive\] or less of blood). Number of spotting days will be assessed per 90-day reference period (RP).

    Time frame: Up to 24 months

  9. Number of Bleeding and/or Spotting Days During Extended-Duration Use as Assessed in 90-day Reference Periods

    Participants will record daily vaginal bleeding and/or spotting in an electronic diary. A bleeding day is defined as any day (24 hours) with bloody vaginal discharge requiring more than one sanitary product (i.e., pad, panty liner, tampon, or menstrual cup) or, if only a menstrual cup is used, more than 5 mL of blood accumulates. A spotting day is defined as any day (24 hours) with bloody vaginal discharge requiring at most one sanitary product (i.e. pad, panty liner, tampon, or menstrual cup containing 5 ml \[inclusive\] or less of blood). Number of bleeding and/or spotting days will be assessed per 90-day reference period (RP).

    Time frame: Up to 24 months

  10. Mean Length of Bleeding and/or Spotting Episodes During Extended-Duration Use as Assessed in 90-day Reference Periods

    Participants will record daily vaginal bleeding and/or spotting in an electronic diary (eDiary). A bleeding day is defined as any day (24 hours) with bloody vaginal discharge requiring more than one sanitary product (i.e., pad, panty liner, tampon, or menstrual cup) or, if only a menstrual cup is used, more than 5 mL of blood accumulates. A spotting day is defined as any day (24 hours) with bloody vaginal discharge requiring at most one sanitary product (i.e. pad, panty liner, tampon, or menstrual cup containing 5 ml \[inclusive\] or less of blood). A bleeding and/or spotting episode is defined as one or more consecutive days during which bleeding and/or spotting is recorded in the eDiary, bounded bleeding/spotting-free days.

    Time frame: Up to 24 months

  11. Percentage of Participants per 90-day Reference Period with Amenorrhea During Extended-Duration Use

    Participants will record daily vaginal bleeding and/or spotting in an electronic diary (eDiary). Amenorrhea is defined as no bleeding or spotting recorded in the eDiary per 90-day reference period (RP).

    Time frame: Up to 24 months

  12. Percentage of Participants per 90-Day Reference Period with Infrequent Bleeding and/or Spotting During Extended-Duration Use

    Participants will record daily vaginal bleeding and/or spotting in an electronic diary (eDiary). A bleeding day is defined as any day (24 hours) with bloody vaginal discharge requiring more than one sanitary product (i.e., pad, panty liner, tampon, or menstrual cup) or, if only a menstrual cup is used, more than 5 mL of blood accumulates. A spotting day is defined as any day (24 hours) with bloody vaginal discharge requiring at most one sanitary product (i.e. pad, panty liner, tampon, or menstrual cup containing 5 ml \[inclusive\] or less of blood). Infrequent bleeding and/or spotting is defined as less than 3 episodes of bleeding and/or spotting per 90-day reference period (RP).

    Time frame: Up to 24 months

  13. Percentage of Participants per 90-Day Reference Period with Frequent Bleeding and/or Spotting During Extended-Duration Use

    Participants will record daily vaginal bleeding and/or spotting in an electronic diary (eDiary). A bleeding day is defined as any day (24 hours) with bloody vaginal discharge requiring more than one sanitary product (i.e., pad, panty liner, tampon, or menstrual cup) or, if only a menstrual cup is used, more than 5 mL of blood accumulates. A spotting day is defined as any day (24 hours) with bloody vaginal discharge requiring at most one sanitary product (i.e. pad, panty liner, tampon, or menstrual cup containing 5 ml \[inclusive\] or less of blood). Frequent bleeding and/or spotting is defined as more than 5 episodes of bleeding and/or spotting per 90-day reference period (RP).

    Time frame: Up to 24 months

  14. Percentage of Participants per 90-Day Reference Period with Normal Frequency Bleeding and/or Spotting During Extended-Duration Use

    Participants will record daily vaginal bleeding and/or spotting in an electronic diary (eDiary). A bleeding day is defined as any day (24 hours) with bloody vaginal discharge requiring more than one sanitary product (i.e., pad, panty liner, tampon, or menstrual cup) or, if only a menstrual cup is used, more than 5 mL of blood accumulates. A spotting day is defined as any day (24 hours) with bloody vaginal discharge requiring at most one sanitary product (i.e. pad, panty liner, tampon, or menstrual cup containing 5 ml \[inclusive\] or less of blood). Normal frequency of bleeding and/or spotting is defined as 3 to 5 episodes of bleeding and/or spotting per 90-day reference period (RP).

    Time frame: Up to 24 months

  15. Percentage of Participants per 90-Day Reference Period with Prolonged Bleeding and/or Spotting During Extended-Duration Use

    Participants will record daily vaginal bleeding and/or spotting in an electronic diary (eDiary). A bleeding day is defined as any day (24 hours) with bloody vaginal discharge requiring more than one sanitary product (i.e., pad, panty liner, tampon, or menstrual cup) or, if only a menstrual cup is used, more than 5 mL of blood accumulates. A spotting day is defined as any day (24 hours) with bloody vaginal discharge requiring at most one sanitary product (i.e. pad, panty liner, tampon, or menstrual cup containing 5 ml \[inclusive\] or less of blood). Prolonged bleeding and/or spotting is defined more than 14 continuous days of bleeding and/or spotting, per 90-day reference period (RP).

    Time frame: Up to 24 months

  16. Number of Complications Associated with Implant Removal

    Complications associated with implant removal will include failed implant removal; implant site fibrosis; extension of incision of \>1 cm; removal of a nonpalpable implant; removal of a deeply placed implant; implant removal in an operating room; implant removal requiring general anesthesia; implant removal requiring regional anesthesia; implant removal requiring imaging guidance; nerve injury during implant removal; vascular injury during implant removal; other complications of device removal not previously mentioned.

    Time frame: Up to 24 months

07

Study locations

67 sites
  • Alabama Clinical Therapeutics (Site 0222)
    Birmingham, Alabama 35205, United States
  • Desert Star Family Planning (Site 0193)
    Phoenix, Arizona 85015, United States
  • Precision Trials (Site 0187)
    Phoenix, Arizona 85032, United States
  • Visions Clinical Research Tucson (Site 0134)
    Tucson, Arizona 85712, United States
  • Essential Access Health (Site 0163)
    Los Angeles, California 90010, United States
  • Matrix Clinical Research Inc (Site 0105)
    Los Angeles, California 90057, United States
  • University of California Los Angeles (Site 0119)
    Los Angeles, California 90095, United States
  • University of California, Davis (Site 0124)
    Sacramento, California 95817, United States
  • Stanford University (Site 0112)
    Stanford, California 94305, United States
  • Planned Parenthood of the Rocky Mountains (Site 0196)
    Denver, Colorado 80207, United States
  • Comprehensive Womens Health Center (Site 0194)
    Denver, Colorado 80230, United States
  • Physicians' Research Options, LLC (Site 0166)
    Lakewood, Colorado 80228, United States
  • University Of Florida (Site 0144)
    Jacksonville, Florida 32207, United States
  • Emerald Coast Obstetrics and Gynecology (Site 0203)
    Panama City, Florida 32405, United States
  • Lenus Research & Medical Group Llc (Site 0102)
    Sweetwater, Florida 33172, United States
  • Comprehensive Clinical Trials LLC (Site 0101)
    West Palm Beach, Florida 33409, United States
  • Mount Vernon Clinical Research (Site 0111)
    Sandy Springs, Georgia 30328, United States
  • Rosemark (Site 0177)
    Idaho Falls, Idaho 83404, United States
  • Planned Parenthood of Illinois (PPIL) (Site 0200)
    Chicago, Illinois 60610, United States
  • Indiana University (Site 0220)
    Indianapolis, Indiana 46202, United States
  • McFarland Clinic, PC (Site 0217)
    Ames, Iowa 50010-3014, United States
  • Cypress Medical Research Center (Site 0226)
    Wichita, Kansas 67226, United States
  • Southern Clinical Research Associates (Site 0219)
    Metairie, Louisiana 70001, United States
  • Johns Hopkins Bayview Medical Center (Site 0225)
    Baltimore, Maryland 21224, United States
  • Boston University Medical Center (Site 0167)
    Boston, Massachusetts 02118, United States
  • Planned Parenthood League of Massachusetts (Site 0135)
    Boston, Massachusetts 02215, United States
  • Michigan Medicine (Site 0108)
    Ann Arbor, Michigan 48109, United States
  • Saginaw Valley Medical Research Group, LLC (Site 0198)
    Saginaw, Michigan 48604, United States
  • Planned Parenthood of North Central States (PPNCS) (Site 0113)
    Minneapolis, Minnesota 55408, United States
  • Metro Jackson OBGYN/SKYCRNG (Site 0233)
    Jackson, Mississippi 39202, United States
  • Planned Parenthood of the Saint Louis Region & Southwest Missouri (Site 0158)
    St Louis, Missouri 63108, United States
  • Washington University (Site 0129)
    St Louis, Missouri 63108, United States
  • Office of Edmond Pack, MD (Site 0168)
    Las Vegas, Nevada 89113, United States
  • Capital Health OB/GYN- Lawrenceville (Site 0190)
    Lawrenceville, New Jersey 08648, United States
  • Albuquerque Clinical Trials (Site 0210)
    Albuquerque, New Mexico 87102, United States
  • Bosque Women's Care (Site 0211)
    Albuquerque, New Mexico 87111, United States
  • Icahn School of Medicine at Mount Sinai (Site 0155)
    New York, New York 10029, United States
  • Columbia Univ. Medical Center (Site 0118)
    New York, New York 10032, United States
  • Montefiore Medical Center (Site 0103)
    The Bronx, New York 10461, United States
  • Carolina Women's Research and Wellness Center (Site 0154)
    Durham, North Carolina 27713, United States
  • Eastern Carolina Women's Center (Site 0159)
    New Bern, North Carolina 28562, United States
  • Velocity Clinical Research, Cincinnati (Site 0230)
    Cincinnati, Ohio 45242, United States
  • The Ohio State University (Site 0176)
    Columbus, Ohio 43210, United States
  • HWC Women's Research Center (Site 0199)
    Englewood, Ohio 45322, United States
  • Oregon Health Sciences University Hospital (Site 0128)
    Portland, Oregon 97239, United States
  • OB/GYN Associates of Erie (Site 0183)
    Erie, Pennsylvania 16507, United States
  • University of Pittsburgh - Magee Womens Hospital (Site 0100)
    Pittsburgh, Pennsylvania 15213, United States
  • Palmetto Clinical Research (Site 0133)
    Summerville, South Carolina 29485, United States
  • University of Tennessee Medical Center Knoxville (Site 0218)
    Knoxville, Tennessee 37920, United States
  • Gadolin Research (Site 0232)
    Beaumont, Texas 77702, United States
  • Signature Gyn Services (Site 0201)
    Fort Worth, Texas 76104, United States
  • Planned Parenthood of the Gulf Coast (Site 0106)
    Houston, Texas 77023, United States
  • University of Texas Health Science Center (Site 0178)
    Houston, Texas 77030, United States
  • Centex Studies, Inc. (Site 0171)
    Houston, Texas 77058, United States
  • Advances in Health, Inc. (Site 0209)
    Pearland, Texas 77030, United States
  • Tekton Research - Floyd Curl Drive (Site 0228)
    San Antonio, Texas 78229, United States
  • Physicians' Research Options, LLC (Site 0204)
    Pleasant Grove, Utah 84062, United States
  • JBR Clinical Research (Site 0174)
    Salt Lake City, Utah 84107, United States
  • Tidewater Clinical Research Inc (Site 0162)
    Norfolk, Virginia 23502, United States
  • Eastern Virginia Medical School (Site 0146)
    Norfolk, Virginia 23507, United States
  • Multicare Health System Institute for Research and Innovation (Site 0188)
    Cheney, Washington 99004, United States
  • Seattle Women's: Health, Research, Gynecology (Site 0149)
    Seattle, Washington 98105, United States
  • Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky (Site 0110)
    Seattle, Washington 98122, United States
  • North Spokane Women's Clinic (Site 0137)
    Spokane, Washington 99207, United States
  • Advance Medical Concept PSC (Site 0313)
    Cidra, PR 00739, Puerto Rico
  • Clinical Research Puerto Rico Inc (Site 0302)
    San Juan, PR 00909, Puerto Rico
  • FDI Clinical Research (Site 0305)
    San Juan, PR 00927, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2024, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 12, 2020
StartActual
Nov 19, 2020
Primary completionActual
Dec 30, 2024
CompletionActual
Dec 30, 2024
Results delay requested
Dec 19, 2025
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04626596
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Nov 19, 2020
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Feb 18, 2026

Study contacts

Clinical Lead
study director · Organon and Co

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etonogestrel

Start the discussion